Saol Therapeutics Secures $115 Million Investment from Oaktree for SL1009 Launch Preparation
Saol Therapeutics has entered into a definitive agreement with funds managed by Oaktree Capital to receive up to $115 million in milestone-based financing. The investment will support the launch readiness of Saol's investigational drug, SL1009 (sodium dichloroacetate), for treating pyruvate dehydrogenase complex deficiency (PDCD). An NDA resubmission was filed on June 30, 2026, with an FDA target action date of December 30. The remaining funds will be released upon achieving regulatory and commercial milestones. The capital also aims to expand the lifecycle opportunities for Saol's portfolio, including developing SL1009 for Congenital Lactic Acidosis (CLA) and advancing SL1002 into additional pain indications and spasticity. Additionally, Saol received a Notice of Allowance from the USPTO covering a method of administering SL1009 to patients on a ketogenic diet.
Topics: clinical-stage pharmaceutical FDA NDA resubmission funding agreement pipeline development